RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
…
Rockwood Research

Corporate filings · Event Monitor · Free for all

← Back

Denali Therapeutics Inc.

DNLI

Biological Products, (No Diagnostic Substances) · SIC 2836 · CIK 0001714899

SHARE:XLINKEDINEMAIL
Revenue FY2025
$0.00B
Net Income
$(0.51B)
EPS (Basic)
$-2.97
Net Margin
—
ROE
-50.6%
Total Equity
$1.01B
Shares Out
160M

Denali Therapeutics Inc. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2016–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Revenue & Net Income (10Y)

Margin Trends

Investor Ownership · 4 funds in our universe

FundPosition Value% of AUMQoQ ChgWeight
Baker Bros. Advisors
Baker Bros. Advisors
$96.0M
0.3%
+0.1%
Holocene Advisors
Holocene Advisors
$100.4M
0.2%
+22.2%
Alps Advisors
Alps Advisors
$4.1M
0.0%
+24.2%
Capital Research Global Investors
Capital Research Global Investors
$66.0M
0.0%
+2.0%

Insider Transactions

Reading stored insider transactions…